FDA Knew Puberty Blockers Increase 'Suicidality' in 2017

"Safety review" by Division of Metabolism and Endocrinology Products contradicts narrative promoted by HHS's Rachel Levine, FDA's child health and endocrinology leaders. Insurance coverage invoked to justify approval for "gender transition." Read Full Article »